Background: Certain ovarian cancers that were previously common in postmenopausal women are now increasingly observed in women of reproductive age. The research on using β-HCG as a diagnostic biomarker for ovarian cancer in women of reproductive age is ongoing. Aim: This study assessed the level of serum β-HCG in non-pregnant women of reproductive age and determined its potential association with suspicious ovarian ultrasonography results. Methods: The study was conducted in Port Harcourt, Nigeria. This study adopted a cross-sectional design on a quota sample of 224 case notes of women aged 18 - 40 years obtained from eight diagnostic centres. A data extraction form was used for data collection. Data analysis employed descriptive statistics, Chi-square, Fisher’s exact test, and Odds Ratio at 95% confidence and 5% significance levels. Results: About 5.8% of the participants exhibited detectable levels of serum β-HCG above 5 IU/L (World Health Organization reference) at a mean concentration of 5.87 (±1.75) IU/L. About 4.0% of the participants had suspicious ovarian lesions identified through ultrasonography. Participants with elevated serum β-HCG levels above the WHO reference were 59 times more likely to have suspicious ovarian lesions (Odds ratio: 59.4, 95%CI: 12.3 - 287.8, p < 0.001). There was a significant association between serum β-HCG level and age (p = 0.041) as well as parity (p < 0.001). Conclusion: Serum β-HCG levels above the WHO reference in non-pregnant women were associated with suspicious ovarian lesions. More rigorous primary research, systematic reviews, and meta-analyses are needed to confirm the findings of this study.
References
[1]
Caeiro, C., Leão, I., Oliveira, I., Sousa, I. and AndrÉ, T. (2022) Recurrent Ovarian Cancer with BRCAness Phenotype: A Treatment Challenge. Advances in Therapy, 39, 5289-5299. https://doi.org/10.1007/s12325-022-02259-2
[2]
Karim, S.M.H. and Fattah, C.N. (2023) The Correlation between Women’s Various Gynaecological Diseases to Ovarian Cancer in Sulaimaniyah City, Iraq. Journal of International Medical Research, 51. https://doi.org/10.1177/03000605231158949
[3]
Wu, W., Gao, H., Li, X., Peng, S., Yu, J., Liu, N., Zhan, G., Zhu, Y., Wang, K. and Guo, X. (2019) β-HCG Promotes Epithelial Ovarian Cancer Metastasis through ERK/MMP2 Signaling Pathway. Cell Cycle, 18, 46-59. https://doi.org/10.1080/15384101.2018.1558869
[4]
Śliwa, A., Kubiczak, M., Szczerba, A., Walkowiak, G., Nowak-Markwitz, E., Burczyńska, B., Butler, S., Iles, R., Białas, P. and Jankowska, A. (2019) Regulation of Human Chorionic Gonadotropin β Subunit Expression in Ovarian Cancer. BMC Cancer, 19, Article No. 746. https://doi.org/10.1186/s12885-019-5960-2
[5]
Demir, A.Y., Musson, R.E., Schöls, W.A. and Duk, J.M. (2019) Pregnancy, Malignancy or Mother Nature? Persistence of High HCG Levels in a Perimenopausal Woman. BMJ Case Reports, 12, e227203. https://doi.org/10.1136/bcr-2018-227203
[6]
Nome, R.V., Bjøro, T., Paus, E., Bjerner, J., Fosså, S.D., Steen, R., Nustad, K. and Bolstad, N. (2018) Lowered Reference Limits for HCG Improve Follow-Up of Patients with HCG-Producing Tumors. Clinical Biochemistry, 52, 73-79. https://doi.org/10.1016/j.clinbiochem.2017.11.016
[7]
Patel, K.K., Qavi, A.J., Hock, K.G. and Gronowski, A.M. (2017) Establishing Reference Intervals for HCG in Postmenopausal Women. Clinical Biochemistry, 50, 234-237. https://doi.org/10.1016/j.clinbiochem.2016.11.017
[8]
Deng, H., Chen, M., Guo, X., Heng, J., Xu, X., Peng, L., Jiang, H., Li, G., Day, JX., Li, J., Shan, D., Li, Y., Zhou, Y., Liu, B., Dai, L., Wang, X. and Wang, J. (2019) Comprehensive Analysis of Serum Tumor Markers and BRCA1/2 Germline Mutations in Chinese Ovarian Cancer Patients. Molecular Genetics & Genomic Medicine, 7, e672. https://doi.org/10.1002/mgg3.672
[9]
Djurdjevic, S., Maksimovic, M., Pantelic, M., Golubovic, A. and Curcic, A. (2011) Usefulness of β hCG as Tumor Marker in the Diagnosis and Follow Up of Patients with Ovarian Cancer. Journal of BUON, 16, 715-721.
[10]
El-Hage, L. and Hatipoglu, B. (2021) Elevated hCG Can Be a Benign Finding in Perimenopausal and Postmenopausal Women. Cleveland Clinic Journal of Medicine, 88, 635-639. https://doi.org/10.3949/ccjm.88a.18069
[11]
Heidegger, H. and Jeschke, U. (2018) Human Chorionic Gonadotropin (HCG)-An Endocrine, Regulator of Gestation and Cancer. International Journal of Molecular Sciences, 19, Article 1502. https://doi.org/10.3390/ijms19051502
[12]
McCash, S.I., Goldfrank, D.J., Pessin, M.S. and Ramanathan, L.V. (2017) Reducing False-Positive Pregnancy Test Results in Patients with Cancer. Obstetrics & Gynecology, 130, 825-829. https://doi.org/10.1097/AOG.0000000000002244
[13]
Charan, J. and Biswas, T. (2013) How to Calculate Sample Size for Different Study Designs in Medical Research? Indian Journal of Psychological Medicine, 35, 121-126. https://doi.org/10.4103/0253-7176.116232
[14]
Cole, L.A., Khanlian, S.A. and Muller C.Y. (2008) Detection of Perimenopause or Postmenopause Human Chorionic Gonadotropin: An Unnecessary Source of Alarm. American Journal of Obstetrics & Gynecology, 198, 275.E1-275.E7. https://doi.org/10.1016/j.ajog.2007.09.034
[15]
Bolarinwa, O.A. (2020) Sample Size Estimation for Health and Social Science Researchers: The Principles and Considerations for Different Study Designs. Nigerian Postgraduate Medical Journal, 27, 67-75. https://doi.org/10.4103/npmj.npmj_19_20
[16]
Smith-Bindman, R., Poder, L, Johnson, E. and Miglioretti, D.L. (2019) Risk of Malignant Ovarian Cancer Based on Ultrasonography Findings in a Large Unselected Population. JAMA Internal Medicine, 179, 71-77. https://doi.org/10.1001/jamainternmed.2018.5113
[17]
Son, J., Carr, C., Yao, M., Radeva, M., Priyadarshini, A., Marquard, J., Michener, C.M. and AlHilli, M. (2020) Endometrial Cancer in Young Women: Prognostic Factors and Treatment Outcomes in Women Aged ≤ 40 Years. International Journal of Gynecologic Cancer, 30, 631-639. https://doi.org/10.1136/ijgc-2019-001105
[18]
Chapman-Davis, E., Zhou, Z.N., Fields, J.C., Frey, M.K., Jordan, B., Sapra, K.J., Chatterjee-Paer, S., Carlson, A.D. and Holcomb, K.M. (2021) Racial and Ethnic Disparities in Genetic Testing at a Hereditary Breast and Ovarian Cancer Center. Journal of General Internal Medicine, 36, 35-42. https://doi.org/10.1007/s11606-020-06064-x
[19]
Lenhard, M., Tsvilina, A., Schumacher, L., Kupka, M., Ditsch, N., Mayr, D., Friese, K. and Jeschke, U. (2012) Human Chorionic Gonadotropin and Its Relation to Grade, Stage and Patient Survival in Ovarian Cancer. BMC Cancer, 12, Article No. 2. https://doi.org/10.1186/1471-2407-12-2
[20]
Mooney, R.A., Arvan, D.A., Saller Jr., D.N., French, C.A. and Peterson, C.J. (1995) Decreased Maternal Serum HCG Levels with Increasing Gravidity and Parity. Obstetrics & Gynecology, 86, 900-905. https://doi.org/10.1016/0029-7844(95)00308-E
